Biotricity (NASDAQ: BTCY) is a modern medical technology company focused on delivering remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement.
Biotricity's Product Videos
Compete with Biotricity?
Ensure that your company and products are accurately represented on our platform.
Biotricity's Products & Differentiators
Real-time cardiac monitor and cloud system, one piece solution, built in cellular technology
Expert Collections containing Biotricity
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Biotricity is included in 5 Expert Collections, including Medical Devices.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)
Companies developing, offering, or using electronic and telecommunication technologies to facilitate the delivery of health & wellness services from a distance. *Columns updated as regularly as possible; priority given to companies with the most and/or most recent funding.
Health Monitoring & Diagnostics
Companies offering products that help assess patients’ state of health and well-being from a distance. Tagged as #RemoteMonitoring&Diagnostics
Latest Biotricity News
Nov 21, 2022
Nov. 21, 2022 8:43 AM ET Biotricity, Inc. (BTCY) By: Ravikash , SA News Editor atiatiati Biotricity (NASDAQ: BTCY ) said it surpassed $10M in annual revenue run rate. The company added that it delivered revenue growth in 9 out of the last 10 consecutive quarters. Last week, Biotricity reported its FQ2 results , which had missed analysts estimates, despite revenue rising about 32% Y/Y. "I am committed to continuing to drive growth and realize our potential. Our focus remains on providing the cardiac health market with disruptive, superior digital and AI technology at competitive pricing with unrivaled support to our customers and physician partnerships," said Biotricity Founder and CEO Waqaas Al-Siddiq. On Nov. 18, Biotricity said that its strategy is to strengthen cash flow, reduce capital expenditures, capture market share, and drive top-line growth. The company noted that it was cross- and up-selling its full suite of cardiac monitoring products. BTCY +7.55% to $1.14 premarket Recommended For You
Biotricity Web Traffic
Biotricity Frequently Asked Questions (FAQ)
When was Biotricity founded?
Biotricity was founded in 2014.
Where is Biotricity's headquarters?
Biotricity's headquarters is located at 203 Redwood Shores Pkwy, Suite 600, Redwood City.
What is Biotricity's latest funding round?
Biotricity's latest funding round is IPO.
Who are the investors of Biotricity?
Investors of Biotricity include MetaSolutions.
Who are Biotricity's competitors?
Competitors of Biotricity include Healionics, Lumenis, BioTelemetry, Cutera, nContact Surgical and 13 more.
What products does Biotricity offer?
Biotricity's products include Bioflux and 1 more.
Compare Biotricity to Competitors
C2C is a medical device company developing a portfolio of medical devices.
Tursiop Technologies Llc is a medical device company. It had developed the Tt1 General Purpose Coil for use in imaging machines.
ES Vascular Ltd. developed first ever surgical stapling devices for endovascular surgery. These devices aim to transform vascular surgery by shortening procedural times, and by simplifying and potentially increasing the safety of the most common vascular interventions. The company is currently developing three product lines for open AAA, endovascular AAA and Femoro-Pop bypass procedures. Its first products are anticipated to enter the market in 2008.nCompany Snapshotn Started in 2000 in Israel by Prof. Shifrin together with group of engineers and leading vascular surgeons from the US and Europe;n Developed a ever vascular stapling technology for stapling synthetic grafts to the aortan Developed endovascular devices for EVAR and SFA procedures
Medical devices for the treatment of severe gastrointestinal disorders
Gaymar Industries is a manufacturer of specialty medical devices
Spineworks Medical, Inc. designs and manufactures medical devices for spinal surgery.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.